Vyne Therapeutics holds shareholder special meeting on merger proposals

Vyne Therapeutics held a special shareholder meeting on July 16, 2026 focused on a merger with Yarrow.

Shareholders authorized the share issuance to Yarrow holders under the merger agreement, clearing the vote required to proceed with the transaction.

A reverse stock split was adopted, with the final ratio to be set later by the board within a 1-for-10 to 1-for-70 range.

An increase in authorized common shares to 300 million was adopted.

The Yarrow Bioscience 2026 Stock Incentive Plan was adopted.